Akeso (HKG:9926) reported an attributable loss of 424.2 million yuan for the first half, narrowing from a loss of 570.1 million a year earlier.
Loss per share stood at 0.46 yuan, compared with 0.64 yuan in the year-ago period, according to a Thursday filing with the Hong Kong Exchange.
The biotech company's revenue increased 28% year over year to 1.81 billion yuan for the six months ended June 30 from 1.41 billion yuan.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.